- Home
- BANX vs PROK Comparison
BANX vs PROK Comparison
Compare BANX & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANX
- PROK
- Stock Information
- Founded
- BANX 2013
- PROK 2015
- Country
- BANX United States
- PROK United States
- Employees
- BANX N/A
- PROK N/A
- Industry
- BANX Trusts Except Educational Religious and Charitable
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BANX Finance
- PROK Health Care
- Exchange
- BANX Nasdaq
- PROK Nasdaq
- Market Cap
- BANX 149.0M
- PROK 126.8M
- IPO Year
- BANX N/A
- PROK N/A
- Fundamental
- Price
- BANX $20.24
- PROK $0.79
- Analyst Decision
- BANX
- PROK Buy
- Analyst Count
- BANX 0
- PROK 4
- Target Price
- BANX N/A
- PROK $5.00
- AVG Volume (30 Days)
- BANX 25.8K
- PROK 1.1M
- Earning Date
- BANX 06-13-2025
- PROK 05-09-2025
- Dividend Yield
- BANX 10.45%
- PROK N/A
- EPS Growth
- BANX N/A
- PROK N/A
- EPS
- BANX 2.35
- PROK N/A
- Revenue
- BANX $29,467,794.00
- PROK $76,000.00
- Revenue This Year
- BANX N/A
- PROK N/A
- Revenue Next Year
- BANX N/A
- PROK N/A
- P/E Ratio
- BANX $8.61
- PROK N/A
- Revenue Growth
- BANX 2.73
- PROK N/A
- 52 Week Low
- BANX $17.91
- PROK $0.46
- 52 Week High
- BANX $21.67
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- BANX 51.50
- PROK 45.47
- Support Level
- BANX $18.37
- PROK $0.65
- Resistance Level
- BANX $19.24
- PROK $1.18
- Average True Range (ATR)
- BANX 0.67
- PROK 0.17
- MACD
- BANX 0.06
- PROK 0.03
- Stochastic Oscillator
- BANX 71.66
- PROK 45.97
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds, and others.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.